Research Links Hypermetabolism and Cachexia in Cancer Patients

Understanding Cachexia

Recent studies have identified a significant correlation between hypermetabolism, characterized by an abnormally high metabolic rate, and cachexia, a wasting syndrome that significantly contributes to mortality in cancer patients. The findings suggest that cachexia is linked to reduced lifespan in individuals with end-stage cancer, highlighting the need for therapeutic approaches aimed at managing hypermetabolism.

Cachexia, often referred to as wasting syndrome, predominantly affects patients with advanced metastatic cancer. It is also observed in the later stages of other progressive diseases, such as HIV/AIDS. Symptoms include loss of appetite, weight loss, muscle atrophy, and fatigue. While anorexia is commonly associated with cachexia, the specific role of metabolism in this condition remains poorly understood.

Study Overview

Researchers from Paris Descartes University have published their findings in the American Journal of Clinical Nutrition. The study investigates whether hypermetabolism could serve as an early indicator of cancer cachexia and whether addressing this issue could positively impact patient survival.

To explore the relationship between metabolism and cachexia in cancer, the researchers measured resting energy expenditure (REE), estimated energy balance (the difference between REE and daily caloric intake), clinical and biological markers of cachexia, and patient survival rates before and after cancer treatments. They compared hypometabolic (low metabolism), normometabolic (normal metabolism), and hypermetabolic patients.

Research Findings

The study analyzed data from 390 patients, revealing that 49% were hypermetabolic, 30% were normometabolic, and 21% were hypometabolic. Despite similar caloric intake across all groups, hypermetabolic patients exhibited a greater tendency to expend more energy than they consumed at rest.

Key findings included:
– Weight loss: 48% in hypermetabolic patients versus 34% in normometabolic patients.
– Performance status (PS): 40% of hypermetabolic patients had a PS greater than or equal to 2, compared to 29% in normometabolic patients.
– Inflammation markers: 52% of hypermetabolic patients had C-reactive protein (CRP) levels exceeding 10 mg/L, versus 33% in the normometabolic group.
– Albumin levels: 35% of hypermetabolic patients had levels below 35 g/L, while only 14% in the normometabolic group did.
– Nutritional risk index (NRI): 76% of hypermetabolic patients had an NRI of 97.5 or lower, compared to 32% of normometabolic patients.

In the subgroup of patients with metastatic cancer, those classified as hypermetabolic exhibited a shorter average survival time of 14.6 months compared to 21.4 months for normometabolic patients.

Conclusions and Implications

The study concludes that hypermetabolism is correlated with markers of cancer cachexia and contributes to decreased survival in metastatic cancer patients. The authors advocate for the early detection of hypermetabolism along with the development of strategies to address this metabolic state, aiming to mitigate or prevent the onset of cachexia.

However, the study acknowledges limitations, including the heterogeneous nature of the patient populations and the lack of experimental data specific to different cancer types.

Written By: Kenneth Dominguez, PhD